CD38 CAR‐T cells have been developed for phase 1/2 clinical trials, and a double‐targeted DCAR‐T cell, which targets CD38 and SLAMF7, has also been constructed for the treatment of MM. Here, CD38 is linked to Miyoshi myopathy.